Osteoporotic Lumbar Degenerative Disease
Conditions
Interventions
VK2+VD3 Group:Starting one week after surgery, oral intake of vitamin K2 (45 mg/day), vitamin D3 (250 IU/day), and calcium supplements (1.2 g/day) will be taken for 6 months.
Control Group:Starting from one week after surgery, take oral vitamin D3 (250 IU/day) and calcium supplements (1.2 g/day) for 6 months.
Sponsors
Shandong Wendeng Orthopedic Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged between 50 and 80 years; 2. Patients diagnosed with lumbar spinal stenosis, degenerative spondylolisthesis, or isthmic spondylolisthesis based on clinical symptoms and imaging findings from MRI, CT, and X-ray examinations; 3. Patients confirmed to have osteoporosis (T-score <= -2.5) via dual-energy X-ray absorptiometry (DXA) and requiring pharmacological intervention; 4. Patients in whom conservative treatment was ineffective and who require single-channel endoscopic lumbar interbody fusion with percutaneous pedicle screw fixation.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of previous lumbar surgery or requiring multi-level lumbar fusion; 2. Patients who have been using medications that affect bone metabolism long-term (e.g., bisphosphonates, PTH analogs); 3. Patients who are allergic or intolerant to vitamin K2 or D3; 4. Patients currently undergoing warfarin treatment; 5. Patients with severe cardiovascular or pulmonary diseases that preclude surgical tolerance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intervertebral Fusion; | — |
Secondary
| Measure | Time frame |
|---|---|
| the Japanese Orthopaedic Association Back Pain Evaluation Questionnaire (JOA-BPEQ);the Oswestry Disability Index;procollagen type I N-terminal propeptide(P1NP);C-terminal telopeptide(ß-CROSS); | — |
Countries
China
Contacts
Public ContactSong Fu
Shandong Wendeng Orthopedic Hospital
Outcome results
None listed